Cataract drugs in development, 2023
The Cataract drugs in development market research report provides comprehensive information on the therapeutics under development for Cataract, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cataract. Buy the report here.The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cataract and features dormant and discontinued products.GlobalData tracks 19 drugs in development for Cataract by 17 companies/universities/institutes. The top development phase for Cataract is preclinical with 13 drugs in that stage. The Cataract pipeline has 17 drugs in development by companies and two by universities/ institutes. Some of the companies in the Cataract pipeline products market are: Plex Pharmaceuticals, Optus Pharmaceutical and Caregen.The key targets in the Cataract pipeline products market include Alpha Crystallin A Chain (Heat Shock Protein Beta 4 or HSPB4 or CRYAA), Alpha Crystallin B Chain (Heat Shock Protein Beta 5 or Renal Carcinoma Antigen NY REN 27 or Rosenthal Fiber Component or HSPB5 or CRYAB), and Calpain 1 Catalytic Subunit (Calcium Activated Neutral Proteinase 1 or Calpain Mu Type or Calpain 1 Large Subunit or Cell Proliferation Inducing Gene 30 Protein or Micromolar Calpain or CAPN1 or EC 3.4.22.52).The key mechanisms of action in the Cataract pipeline product include Alpha Crystallin A Chain (Heat Shock Protein Beta 4 or HSPB4 or CRYAA) Activator with two drugs in Preclinical. The Cataract pipeline products include six routes of administration with the top ROA being Ophthalmic and five key molecule types in the Cataract pipeline products market including Small Molecule, and Synthetic Peptide.Cataract overviewA cataract is a clouding of the normally clear lens of eye that affects vision. Symptoms include clouded, blurred, or dim vision; increasing difficulty with vision at night; fading or yellowing of colors; double vision in a single eye; and frequent prescription changes in eye wear. Risk factors include age, diabetes, excessive alcohol consumption, high blood pressure, obesity, and smoking.For a complete picture of Cataract's pipeline drug market, buy the report here.
GlobalData tracks 19 drugs in development for Cataract by 17 companies/universities/institutes. The top development phase for Cataract is preclinical, with 13 drugs in that stage.
What's Your Reaction?
